Kyungnam Pharm Co., Ltd.
KKRX:0539501,766.00
KRW
-25.00
(-1.40%)
ISIN
KR7053950002
Return %
Stock
S&P 500
1Y
-37.49
14.39
3Y
-61.57
81.42
5Y
-91.50
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 238
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Uiryeong-gun South Korea
- IPO Date
- Nov 6, 2001
- Website
- kyungnampharm.co.kr
- Similar Companies
- Business
- Kyungnam Pharm Co., Ltd. is a South Korea-based pharmaceutical and consumer healthcare company that specializes in the research, development, manufacture, and commercialization of over-the-counter (OTC) pharmaceuticals, prescription medications, health functional foods, quasi-drugs, and wellness products. The company organizes its business operations into distinct segments, encompassing Over-the-Counter Pharmaceuticals, Health Functional Foods, Prescription Drugs, and Commercial Distribution. Its systematic product and service offerings comprise over-the-counter and prescription therapeutic formulations, including PM brand antifungal and athlete's foot remedies; Minol Troche sore throat and antitussive lozenges; Jahasengryeok human placenta extract restorative tonics; Placencia injectable solutions; antipyretic analgesics, cold remedies, and digestive treatments; health functional foods and dietary supplements, anchored by its flagship Lemona powdered vitamin C brand, Lemona Pink, and Lemona Gyeol Collagen; the Kalo line of diet and weight-management formulations; probiotics, calcium supplements, and multivitamin complexes; quasi-drugs and sanitary goods, including insect repellents, sanitizers, and oral hygiene products; and commercial trade services involving the import, export, and distribution of select consumer commodities and beverages. Kyungnam Pharm supplies its products across domestic hospital networks, community pharmacies, retail drugstores, duty-free shops, and major e-commerce platforms, while exporting to international markets across the Asia-Pacific region, North America, and Europe, including China, Japan, Vietnam, Taiwan, the United States, and Canada. In recent corporate developments, Kyungnam Pharm underwent major ownership restructuring; in April 2024, Metaplex and affiliated entities became the company's largest shareholder with a 31.13% equity stake following a third-party allotment capital increase, succeeding Billions (formerly Blade Entertainment). Strategic governance and capital alignments were subsequently integrated with Humasis following its acquisition of Billions in May 2024. To bolster financial stability and support operational expansion, the company executed a further third-party allotment capital increase of approximately KRW 6.5 billion in July 2026. Operationally, Kyungnam Pharm expanded its corporate business scope into the import and distribution of wine and spirits to diversify revenue streams, while revitalizing consumer engagement through strategic intellectual property collaborations for its Kalo dietary line and broadening global export channels for its Lemona brand. Founded in 1957, Kyungnam Pharm Co., Ltd. is headquartered in Uiryeong-gun, Gyeongsangnam-do, South Korea, with principal manufacturing and administrative operations in Asan and Seoul.